Skip to content

Molecular mechanism and further treatment of Apatinib resistance in advanced gastric cancer

Molecular mechanism and further treatment of Apatinib resistance in advanced gastric cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017566
Enrollment
Unknown
Registered
2018-08-04
Start date
2018-09-01
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Case series:Nil

Sponsors

The Second Hospital of Tianjin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. aged = 18 years; 2. patient diagnosed with gastric cancer by histology or cytology; 3. Patients who have undergone chemoradiotherapy or targeted therapy and are resistant to apatinib 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; 5. adequate liver and renal function at the start of the trial; 6. Each centres institutional review board or independent ethics committee approved the protocol; 7. The trial followed the guiding principles of the Declaration of Helsinki and good clinical practice, and complied with all local laws and regulations. Participants provided written informed consent before enrollment.

Exclusion criteria

Exclusion criteria: 1. Patients whose pathological type or tumor grade is not clear; 2. There are other malignant tumors at the same time; 3. At the same time, suffering from other serious diseases that may affect follow-up and short-term survival; 4. There are social/psychological problems, etc., and the researcher judges that it is not suitable for participation in the study; 5. Cannot receive enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) for clinical follow-up.

Design outcomes

Primary

MeasureTime frame
PFS;

Countries

China

Contacts

Public ContactHaitao Wang

The Second Hospital of Tianjin Medical University

peterrock2000@126.com+86 18630955984

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026